CRDF - CIK 0001213037
Cardiff Oncology, Inc. (CRDF) reported net income of -$45.85K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$45.85K | -0.9% |
| FY 2024 | -$45.43K | -9.6% |
| FY 2023 | -$41.44K | +99.9% |
| FY 2022 | -$38.70M | -36.8% |
| FY 2021 | -$28.29M | -46.5% |
| FY 2020 | -$19.31M | -17.6% |
| FY 2019 | -$16.41M | +0.3% |
| FY 2018 | -$16.46M | +33.9% |
| FY 2017 |
Cardiff Oncology, Inc. (CRDF) reported net income of -$45.85K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Cardiff Oncology, Inc.'s net income grew from -$2.24M to -$45.85K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$24.91M |
| +36.5% |
| FY 2016 | -$39.20M | -42.7% |
| FY 2015 | -$27.47M | -91.8% |
| FY 2014 | -$14.33M | -21.3% |
| FY 2013 | -$11.81M | -2.1% |
| FY 2012 | -$11.57M | -416.5% |
| FY 2011 | -$2.24M | - |